- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Mylan launches generic drug for kidney transplant patients
- Roxane Labs' generic prostate drug gets tentative approval from FDA
PITTSBURGH The Food and Drug Administration has approved a generic treatment for organ transplant patients.
Mylan announced Tuesday the approval of tacrolimus capsules in the 0.5-mg, 1-mg and 5-mg strengths, and said it plans to launch the drug immediately. The drug is used to prevent rejection of transplanted organs.
Tacrolimus capsules are a generic version of Astellas’ Prograf. The branded version of the drug and generic versions had sales of around $944 million during the 12-month period ended in June, according to IMS Health.